Is the Structure Therapeutics (GPCR) investment thesis intact?

Yes. Readouts currently rates the Structure Therapeutics Thesis Intact. Structure's oral GLP-1 pill aleniglipron is in Phase 3, with three data sets due.

What is the next catalyst for Structure Therapeutics (GPCR)?

The next dated event is Phase 1 start for ACCG-3535, expected Q4 2026, as stated by the company. Also ahead: Phase 2 final results for Aleniglipron, expected Q4 2026.

How long will Structure Therapeutics' cash last?

Structure Therapeutics has said its cash will fund operations through end of 2028 (guidance as of August 6, 2026). It reported $1.3 billion in cash as of June 30, 2026.

GPCRStructure Therapeutics Inc.

Market reactionShares rose 10% on Nov 6.

IntactLast material event Sep 8, 2026 · Updated Oct 25, 2026

Structure's oral GLP-1 pill aleniglipron is in Phase 3, with three data sets due

Structure Therapeutics is a clinical-stage company developing oral small-molecule drugs for obesity, led by the GLP-1 receptor agonist aleniglipron; none of its products is approved.

Structure's case rests on aleniglipron, a once-daily oral small-molecule GLP-1 drug. In Phase 2 ACCESS II it cut weight by up to 16.3% more than placebo at 44 weeks. The two Phase 3 ACCOMPLISH trials, with up to 4,700 patients, began in August, with topline data due in the second half of 2028. Body composition, type 2 diabetes and SWITCH data are due in the fourth quarter. ACCG-2671, an oral amylin drug, is in multiple-dose testing. Cash of $1.3 billion funds plans through 2028.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

Body composition, diabetes and SWITCH data support the Phase 3 caseAwaiting evidenceData from all three trials (fourth quarter of 2026).Next: Data from all three trials (fourth quarter of 2026).

Why it is in this state

The evidence, what would weaken it and the source filing

ACCOMPLISH Phase 3 enrolls on scheduleSupportedEnrollment updates.Next: Enrollment updates.

Why it is in this state

The evidence, what would weaken it and the source filing

ACCG-2671 shows weight loss with repeat dosingAwaiting evidenceMultiple-dose topline data (first half of 2027).Next: Multiple-dose topline data (first half of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash funds Phase 3 through 2028SupportedQ3 2026 cash balance.Next: Q3 2026 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Aleniglipron body composition, diabetes and SWITCH data

Tests: Body composition, diabetes and SWITCH data support the Phase 3 case

Fourth quarter of 2026

Do the three trials show fat-focused weight loss, benefit in diabetes and maintained weight after switching from injections?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

-14.7%Sep 8, 2026

Structure's oral GLP-1 pill aleniglipron is in Phase 3, with three data sets due

IntactClinical

+102.5%Dec 8, 2025

Aleniglipron Phase 2b ACCESS: 11.3% placebo-adjusted weight loss at 120mg

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Obesity or overweight

aleniglipron · 2 upcoming · 3 completed

Phase 2 Data: Final

Q4 2026

Phase 3 DataACCOMPLISHPivotal

2H 2028

Obesity or overweight

Aleniglipron + ACCG-2671 · 1 upcoming

Phase 1 Study Initiation

2H 2026

Obesity or overweight

ACCG-3535 · 1 upcoming

Phase 1 Study Initiation

Q4 2026

Obesity or overweight with type 2 diabetes

aleniglipron · 1 upcoming

Phase 2 Data

Q4 2026

Obesity or overweight

ACCG-2671 · 1 upcoming · 1 completed

Phase 1 Data

1H 2027

Obesity or overweight with co-morbidities

ACCG-2671 · 1 completed

Phase 1 Study Initiation

Reported Feb 26, 2026

Obesity or overweight with co-morbidities

aleniglipron · 1 completed

Phase 2b Data: Topline

Reported Dec 8, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Structure Therapeutics (GPCR) investment thesis intact?: Yes. Readouts currently rates the Structure Therapeutics Thesis Intact. Structure's oral GLP-1 pill aleniglipron is in Phase 3, with three data sets due.
What is the next catalyst for Structure Therapeutics (GPCR)?: The next dated event is Phase 1 start for ACCG-3535, expected Q4 2026, as stated by the company. Also ahead: Phase 2 final results for Aleniglipron, expected Q4 2026.
How long will Structure Therapeutics' cash last?: Structure Therapeutics has said its cash will fund operations through end of 2028 (guidance as of August 6, 2026). It reported $1.3 billion in cash as of June 30, 2026.

Other companies we cover in these diseases

Obesity: Ascendis Pharma (ASND)Biohaven (BHVN)BioAge Labs (BIOA)Neumora Therapeutics (NMRA)iBio (IBIO)Lipocine (LPCN)Palatin Technologies (PTN)Viking Therapeutics (VKTX)Fractyl Health (GUTS)Arrowhead Pharmaceuticals (ARWR)

Disease areas: Lung and respiratory diseases, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

12 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.